Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables-Reference-Cited by-同舟云学术

Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables

Published:2017-03-20 Issue:6 Volume:96 Page:995-1003
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Baldini Marina,Marcon A.,Ulivieri F. M.,Seghezzi S.,Cassin R.,Messina C.,Cappellini M. D.,Graziadei G.

Funder

Ministero della Salute

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-017-2959-0.pdf

Reference34 articles.

1. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA (2013) Non-transfusion-dependent thalassemias. Haematologica 98:833–844

2. Weatherall DJ (2012) The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev 26:S3–S6

3. Weatherall DJ (2001) Phenotype-genotype relationships in monogenic disease: lessons from the thalassemias. Nat Rev Genet 2:245–255

4. Taher AT, Musallam KM, El-Beshlawy A et al (2010) Age-related complications in treatment-naïve patients with thalassemia intermedia. Br J Haematol 150:486–489

5. Inati A, Noureldine MA, Mansour A, Abbas HA (2015) Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment. Biomed Res Int 813098

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone densitometry in Thalassemia major: a closer look at pitfalls and operator-related errors in a 10-year follow-up population;La radiologia medica;2024-02-14

2. Bibliometric analysis of publications on trabecular bone score (TBS);Journal of Diabetes & Metabolic Disorders;2023-12-07

3. The influence of iron on bone metabolism disorders;Osteoporosis International;2023-10-19

4. Endocrine Disorders in Adult Beta-Thalassemia Patients: Insights from a Long-Term Follow-Up;Endocrinology Research and Practice;2023-10-06

5. Inhibition of FGF23 is a therapeutic strategy to target hematopoietic stem cell niche defects in β-thalassemia;Science Translational Medicine;2023-05-31